| Literature DB >> 33963458 |
Amy M Dennett1, Bernadette Zappa2, Rachel Wong3, Stephen B Ting4, Kimberley Williams5, Casey L Peiris6.
Abstract
PURPOSE: To establish the feasibility of embedding a flexible, exercise-based rehabilitation program into a cancer treatment unit to allow cancer survivors early exercise support.Entities:
Keywords: Exercise; Referrals; Rehabilitation; Survivorship
Year: 2021 PMID: 33963458 PMCID: PMC8105143 DOI: 10.1007/s00520-021-06261-2
Source DB: PubMed Journal: Support Care Cancer ISSN: 0941-4355 Impact factor: 3.603
Intervention description using the template for description and replication checklist (TIDier)
| Intervention | |
|---|---|
| Brief name | Cancer rehabilitation |
| Why | Exercise during cancer treatment may mitigate side effects and improve treatment efficacy |
| What: materials | • Participants were offered access the hospital gymnasium: - Free weights - Resistance exercise bands - Pin-loaded machines (lateral pull down, leg press, chest press) - Aerobic exercise equipment (exercise bike × 2, treadmill × 1, stairs) - Balance equipment • Participants received a written, individualised home exercise program • Participants were offered a referral to a community exercise program |
| What procedures | |
| Provider | • Two physiotherapists with oncology experience (5.5 years combined) provided by the hospital |
| How | • Face to face sessions (centre-based) or unsupervised sessions (home-based) |
| Where | • Hospital gymnasium or home |
When/how much Type | Aerobic: continuous training prescribed based on 6-min walk test results. Included treadmill, walking, stationary cycle, arm ergometer, exercise pedals Resistance: Prescription based on 10 repetition maximum testing. Pin-loaded machines (leg press, chest press, lat pull down), exercise bands, free weights, body weight exercise (e.g. pushups, stepups, squats, sit to stand) |
| Intensity | Aerobic: Moderate (BORG 3–4) Resistance: 2–3 sets 10–12 RM Progression: Resistance training based on attainment of 2–3 sets of 12, RPE 3–4 Aerobic training aim to work 2–3 for first 2 weeks of the program, working up to 4 on BORG scale by week 8 Hospital-based group opted for 1 or 2 × weekly supervised training |
| Frequency | 2 × weekly strength training (all) 3X weekly aerobic training (all) |
| Session time | Hospital: 60 min (5-min warm-up and cool-down, approx 20 min aerobic, 20 min resistance) Home: 30 min aerobic, resistance not time based |
| Overall duration | 8 weeks |
| Tailoring | • Individualised exercise program based on initial consultation and goals |
| Trial fidelity | • Staff with a background in oncology physiotherapy who had prior formal training were employed by the hospital to provide the intervention. Staff also attended three, 1-h education sessions on exercise and cancer • Exercise log-books were completed for centre-based sessions • Records of the number and duration of completed sessions • Clinical supervision as per standard hospital policy |
Outcome measures of feasibility as described by Bowen’s Framework
| Construct | Measure | Source |
|---|---|---|
Demand To what extent is a new program likely to be used? | • Overall number of referrals • Number of newly diagnosed versus long-term cancer survivors | Routinely collected data |
Acceptability To what extent is a new program, judged as suitable, satisfying or attractive to program deliverers or recipients? | • Number of individual referrers | Routinely collected data |
| • Number of accepted referrals | Exercise records | |
• Number of sessions attended • Participant satisfaction | Survey | |
Implementation To what extent can a new program be successfully delivered to intended participants in some defined, but not fully controlled, context? | • Description of staff training • Stakeholder engagement • Workflow • Equipment • Resources | Project documentation |
Practicality To what extent can a program be carried out with intended participants using existing means, resources, and circumstances and without outside intervention? | • Number of adverse events • Waiting time • Session duration • Ongoing referrals | Routinely collected data |
| • Cost | Log of costs (Supplementary file | |
Limited Efficacy Does the new program process show promise of being successful with the intended population, even in a highly controlled setting? | • 6-min walk test • 5-times STS • Exercise self-efficacy scale • EORTC QLQ-30 | Patient assessment |
EORTC QLQ-30 European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30, STS sit-to-stand
Patient acceptability survey was an instrument designed by the research team (Supplementary File 1)
Fig. 1Flow of referrals
Participant demographics
| Characteristic | |
|---|---|
| Age (years), mean (SD) | 63 (11) |
| Gender (male), | 41 (56) |
| Type of cancer, | |
| Breast | 15 (21) |
| Lower GI | 8 (11) |
| Upper GI | 2 (3) |
| Gynaecological | 3 (4) |
| Multiple myeloma | 11 (15) |
| Lymphoma | 9 (12) |
| Leukaemia | 8 (11) |
| Lung | 5 (7) |
| Renal | 5 (7) |
| Other | 7 (10) |
| Cancer stage, | |
| I | 1 (2) |
| II | 9 (12) |
| III | 21 (29) |
| IV | 19 (26) |
| Unknown | 23 (32) |
| Time since diagnosis, median (range) months | 9 (0 to 298) |
| Current treatment received, | |
| Chemotherapy only | 41 (46) |
| Radiotherapy only | 3 (4) |
| Immunotherapy only | 15 (21) |
| Targeted therapy only | 2 (3) |
| Combination of any of the above | 6 (8) |
| Stem cell transplant | 6 (8) |
| Treatment intent, | |
| Curative | 36 (49) |
| Palliative/maintenance | 37 (51) |
*Stage data missing for most haematological malignancies
Limited efficacy testing, pre and post intervention means of patient outcomes
| Outcome | Baseline, mean (SD) | Post-intervention, mean (SD) | Mean difference, 95%CI | Hedges g effect size, 95% CI |
|---|---|---|---|---|
| 6MWT (m) | 414 (92) | 486 (78) | 0.85 (0.14 to 1.46) | |
| 5 times STS (s) | 11.1 (3.7) | 9.8 (2.9) | 0.39 (0.05 to 0.83) | |
| Self-efficacy for PA (0–90) | 56.4 (17.6) | 60.8 (16.9) | 4.3 ( | 0.25 ( |
| EORTC QLQ-C30 (0–100) | ||||
| Global quality of life | 61 (22) | 69 (16) | 0.43 (0.06 to 0.79) | |
| Physical function | 77 (17) | 82 (15) | 0.32 ( | |
| Role function | 61 (29) | 73 (26) | 0.45 (0.08 to 0.81) | |
| Emotional function | 76 (20) | 83 (17) | 0.41 (0.04 to 0.77) | |
| Cognitive function | 75 (23) | 81 (20) | 0.25 ( | |
| Social function | 63 (26) | 74 (24) | 0.45 (0.08 to 0.82) | |
| Fatigue | 42 (19) | 33 (21) | 0.43 (0.07 to 0.80) | |
| Nausea | 12 (20) | 8 (16) | 0.22 ( | |
| Pain | 23 (25) | 21 (22) | 0.08 ( | |
| Dyspnoea | 29 (27) | 18 (21) | 0.44 (0.07 to 0.80) | |
| Insomnia | 32 (26) | 34 (29) | 2 ( | 0.08 ( |
| Appetite | 16 (23) | 16 (25) | 0 ( | 0.02 ( |
| Constipation | 20 (28) | 14 (24) | 0.26 ( | |
| Diarrhoea | 17 (27) | 13 (22) | 0.16 ( | |
| Financial difficulty | 24 (35) | 20 (31) | 0.12 ( | |
*Significant at < 0.05 **significant at p < 0.01